Myeloprotective effect of high dose medroxyprogesterone acetate on patients receiving cytotoxic chemotherapy
Turkish Journal of Cancer, cilt.28, sa.3, ss.118-123, 1998 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 3
- Basım Tarihi: 1998
- Dergi Adı: Turkish Journal of Cancer
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.118-123
- Anahtar Kelimeler: Chemotherapy, Medroxyprogesterone acetate, Myeloprotection
- Ankara Üniversitesi Adresli: Evet
Özet
In the current study, we aimed to evaluate the myeloprotective effect and possible side effects of high dose medroxyprogesterone acetate (HD-MPA) in cancer patients receiving chemotherapy. Twenty-two patients without prior chemotherapy or radiotherapy, who developed grade 2-3 neutropenia following the first cycle of the chemotherapy regimen were entered into the study. Patients were given HD-MPA (1g/day po) during the second course of chemotherapy. The incidence of leukopenia was significantly lower in the second cycle (chemotherapy+HD-MPA). Other hematological parameters showed no significant differences, and HD-MPA was found to be safe with only minor side effects. Moreover, HD-MPA had positive effects on general tolerance to chemotherapy by decreasing anorexia, increasing sense of well being, and improving performance status. In conclusion, HD-MPA was found to be effective in reducing myelotoxic side effects of chemotherapy.